Quantinno Capital Management LP Has $785,000 Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM

Quantinno Capital Management LP raised its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 166.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,497 shares of the company’s stock after buying an additional 5,305 shares during the period. Quantinno Capital Management LP’s holdings in Mirum Pharmaceuticals were worth $785,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in MIRM. SummitTX Capital L.P. bought a new stake in shares of Mirum Pharmaceuticals during the first quarter worth about $385,000. ABS Direct Equity Fund LLC acquired a new position in Mirum Pharmaceuticals during the 1st quarter valued at about $194,000. Octagon Capital Advisors LP acquired a new position in Mirum Pharmaceuticals during the 1st quarter valued at about $31,308,000. Renaissance Technologies LLC increased its holdings in Mirum Pharmaceuticals by 32.6% during the 1st quarter. Renaissance Technologies LLC now owns 582,085 shares of the company’s stock worth $53,773,000 after purchasing an additional 143,000 shares in the last quarter. Finally, Inceptionr LLC bought a new stake in Mirum Pharmaceuticals during the 1st quarter worth approximately $421,000.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 6,001 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total value of $599,499.90. Following the transaction, the chief financial officer directly owned 36,355 shares in the company, valued at $3,631,864.50. The trade was a 14.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the sale, the chief executive officer owned 194,309 shares of the company’s stock, valued at approximately $18,622,574.56. The trade was a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 93,156 shares of company stock worth $9,763,562 over the last three months. 8.32% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Trading Down 0.8%

Shares of Mirum Pharmaceuticals stock opened at $99.83 on Tuesday. The firm has a market cap of $6.48 billion, a PE ratio of -6.86 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a 1 year low of $63.23 and a 1 year high of $130.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The stock has a fifty day moving average price of $111.04 and a 200-day moving average price of $102.03.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The company had revenue of $176.24 million during the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.Mirum Pharmaceuticals’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.12) earnings per share. Equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on MIRM shares. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 6th. Weiss Ratings upgraded Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th. Stifel Nicolaus set a $136.00 price target on Mirum Pharmaceuticals in a research report on Thursday, May 7th. HC Wainwright cut their price objective on shares of Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Finally, Royal Bank Of Canada reduced their target price on shares of Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $137.33.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.